JGC
SGYP

J. Goldman & Co’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

J. Goldman & Co’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-371,900
Closed -$2.27M – 458
2016
Q4 		$2.27M Buy
+371,900
New +$1.94M 0.15% 166

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

J. Goldman & Co's SGYP Position: Q1 2017 in Review

J. Goldman & Co sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2017, closing a stake of 371,900 shares — an estimated $2.27M sold.

J. Goldman & Co first reported a position in SGYP in Q4 2016 and held it in 1 quarter. The position peaked at $2.27M in Q4 2016. 164 funds tracked by Wall St. Rank hold SGYP as of Q1 2017.

  • J. Goldman & Co reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2017 after selling out during the quarter.
  • J. Goldman & Co sold 371,900 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2017, an estimated $2.27M.
  • J. Goldman & Co first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q4 2016 and held it in 1 quarter.
  • J. Goldman & Co's Synergy Pharmaceuticals, Inc Common Stock position peaked at $2.27M in Q4 2016.
  • 164 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2017.

Based on J. Goldman & Co's 13F filing for Q1 2017, filed 15 May 2017.